{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:59Z","timestamp":1790446979931,"version":"4.1.0"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"name":"Ministry of Health Brazil","award":["20\/2022"],"award-info":[{"award-number":["20\/2022"]}]},{"name":"National Counsel of Technological and Scientific Development","award":["302069\/2022-4"],"award-info":[{"award-number":["302069\/2022-4"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Proper treatment for brucellosis is crucial to eradicate the infection and prevent complications, but there is a notable gap in evidence for pediatric treatment. This study aims to address this gap by reviewing current literature, analyzing the efficacy and safety of brucellosis treatment in children, and identifying areas that require further investigation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic review, following preferred reporting items for systematic reviews and meta-analyses and Cochrane Handbook guidelines, assessed antimicrobial regimens\u2019 efficacy and safety for treating human brucellosis in children. Original human studies with clinical outcomes after drug therapy intervention for children up to 10 years were included. Searches were conducted in Medline, Embase, Cochrane Library and LILACS databases for studies indexed until March 6, 2023. Study selection, data extraction, and bias risk assessment were performed by pairs of reviewers. The quality assessment used Joanna Briggs Institute tools and grading of recommendations assessment, development and evaluation system. Data were analyzed using R software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 1773 records were reviewed, yielding 11 eligible studies encompassing 1156 children. All included studies presented an observational design. The most reported treatment approaches included sulfamethoxazole-trimethoprim with rifampicin or aminoglycosides, with summarized failure rates of 2% (95% confidence interval: 0.0\u20130.49) and 13% (95% confidence interval: 0.06\u20130.29), respectively (very low certainty of evidence). Adverse events and time to defervescence were not reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Sulfamethoxazole-trimethoprim + rifampicin were the most prescribed antibiotics for brucellosis for pediatrics. The study highlights the need for more research with robust designs, and emphasizes uncertainty regarding the efficacy of antimicrobial regimens, emphasizing the importance of further investigations to guide specific treatment protocols for this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004389","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T20:01:58Z","timestamp":1715889718000},"page":"857-866","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Childhood Brucellosis: A Systematic Review"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-3932","authenticated-orcid":false,"given":"Endi","family":"Lanza Galv\u00e3o","sequence":"first","affiliation":[{"name":"From the N\u00facleo de Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte"},{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Reabilita\u00e7\u00e3o e Desempenho Funcional, Departamento de Fisioterapia, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-4794","authenticated-orcid":false,"given":"Kathiaja","family":"Miranda Souza","sequence":"additional","affiliation":[{"name":"From the N\u00facleo de Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-0307","authenticated-orcid":false,"given":"Marina","family":"Gon\u00e7alves de Freitas","sequence":"additional","affiliation":[{"name":"From the N\u00facleo de Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte"},{"name":"SCMED, Brazilian Health Regulatory Agency, Brasilia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-041X","authenticated-orcid":false,"given":"Marina Rocha Fonseca","family":"Souza","sequence":"additional","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Estomatopatologia da Universidade Estadual de Campinas, Piracicaba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3712-5838","authenticated-orcid":false,"given":"Mois\u00e9s Willian Aparecido","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Odontologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-7403","authenticated-orcid":false,"given":"Gl\u00e1ucia","family":"Cota","sequence":"additional","affiliation":[{"name":"From the N\u00facleo de Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-9819","authenticated-orcid":false,"given":"Sarah Nascimento","family":"Silva","sequence":"additional","affiliation":[{"name":"From the N\u00facleo de Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(07)70286-4","article-title":"Human brucellosis.","volume":"7","author":"Franco","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.ajpath.2015.03.003","article-title":"Pathogenesis and immunobiology of brucellosis.","volume":"185","author":"de Figueiredo","year":"2015","journal-title":"Am J Pathol"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1515\/abm-2020-0022","article-title":"Epidemiology of human brucellosis in Nahavand county, Hamadan Province, western Iran: an 8-year (2010-2017) registry-based analysis.","volume":"14","author":"Khazaei","year":"2020","journal-title":"Asian Biomed (Res Rev News)"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1201-9712(02)90108-6","article-title":"Brucellosis in children: clinical observations in 115 cases.","volume":"6","author":"Shaalan","year":"2002","journal-title":"Int J Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/tropej\/50.3.153","article-title":"Childhood brucellosis--a microbiological, epidemiological and clinical study.","volume":"50","author":"Mantur","year":"2004","journal-title":"J Trop Pediatr"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1442-200X.2008.02661.x","article-title":"Presentation, complications, and treatment outcome of brucellosis in Turkish children.","volume":"51","author":"Tanir","year":"2009","journal-title":"Pediatr Int"},{"key":"R7-20250614","first-page":"286","article-title":"Skeletal involvement of Brucella melitensis in children: a systematic review.","volume":"38","author":"Sanaei Dashti","year":"2013","journal-title":"Iran J Med Sci"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2017.1254042","article-title":"Treatment of pulmonary brucellosis: a systematic review.","volume":"15","author":"Solera","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R9-20250614","first-page":"636","article-title":"Treatment of brucellosis: a systematic review of studies in recent twenty years.","volume":"4","author":"Alavi","year":"2013","journal-title":"Caspian J Intern Med"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e0191993","DOI":"10.1371\/journal.pone.0191993","article-title":"Rifampicin versus streptomycin for brucellosis treatment in humans: a meta-analysis of randomized controlled trials.","volume":"13","author":"Meng","year":"2018","journal-title":"PLoS One"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"5712920","DOI":"10.1155\/2018\/5712920","article-title":"A systematic review and meta-analysis of epidemiology and clinical manifestations of human brucellosis in China.","volume":"2018","author":"Zheng","year":"2018","journal-title":"Biomed Res Int"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"e1929","DOI":"10.1371\/journal.pntd.0001929","article-title":"Clinical manifestations of human brucellosis: a systematic review and meta-analysis.","volume":"6","author":"Dean","year":"2012","journal-title":"PLoS NeglTrop Dis"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"976215","DOI":"10.3389\/fvets.2022.976215","article-title":"Prevalence, diagnosis, and manifestations of brucellosis: a systematic review and meta-analysis.","volume":"9","author":"Khoshnood","year":"2022","journal-title":"Front Vet Sci"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14740338.2019.1640678","article-title":"Antibiotic-related adverse events in paediatrics: unique characteristics.","volume":"18","author":"Principi","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity.","volume":"43","author":"S\u00e1nchez","year":"2004","journal-title":"Int J Dermatol"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/ciad357","article-title":"Antibiotic myths for the infectious diseases clinician.","volume":"77","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R21-20250614","first-page":"564","article-title":"Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis.","volume":"134","author":"Roushan","year":"2004","journal-title":"Swiss Med Wkly"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijid.2005.11.007","article-title":"Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.","volume":"11","author":"Ranjbar","year":"2007","journal-title":"Int J Infect Dis"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02309846","article-title":"Childhood brucellosis in north-western Greece: a retrospective analysis.","volume":"155","author":"Galanakis","year":"1996","journal-title":"Eur J Pediatr"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00006454-199703000-00012","article-title":"Failure of short-term antimicrobial therapy in childhood brucellosis.","volume":"16","author":"S\u00e1nchez-Tamayo","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"895","DOI":"10.26719\/1999.5.5.895","article-title":"Brucellosis in children in south Jordan.","volume":"5","author":"Issa","year":"1999","journal-title":"East Mediterr Health J"},{"key":"R26-20250614","first-page":"610","article-title":"Brucellosis in children of Dhofar Region, Oman.","volume":"22","author":"El-Amin","year":"2001","journal-title":"Saudi Med J"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.10.013","article-title":"Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.","volume":"51","author":"Makis","year":"2005","journal-title":"J Infect"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"e1178","DOI":"10.1542\/peds.2007-1874","article-title":"Diagnostic and therapeutic challenges of childhood brucellosis in a nonendemic country.","volume":"121","author":"Shen","year":"2008","journal-title":"Pediatrics"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1016\/j.ijid.2011.08.002","article-title":"A multicenter retrospective study of childhood brucellosis in Chicago, Illinois from 1986 to 2008.","volume":"15","author":"Logan","year":"2011","journal-title":"Int J Infect Dis"},{"key":"R30-20250614","article-title":"Epidemiological and clinical features of Brucella arthritis in 24 children - PubMed."},{"key":"R31-20250614","first-page":"123","article-title":"Evaluation of childhood brucellosis in the central Black Sea region.","volume":"57","author":"\u00c7irakli","year":"2015","journal-title":"Turk J Pediatr"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/0256-4947.81543","article-title":"Epidemiological and clinical features of Brucella arthritis in 24 children.","volume":"31","author":"Zamani","year":"2011","journal-title":"Ann Saudi Med"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00431-016-2785-8","article-title":"Clinical manifestations and laboratory test results on 173 children with brucellosis. EAPS Congress 2016: October 21-25, 2016.","volume":"175","author":"Hasanjani Roushan","year":"2016","journal-title":"Eur J Pediatr"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.apjtm.2015.11.009","article-title":"Childhood brucellosis: review of 317 cases.","volume":"8","author":"Bosilkovski","year":"2015","journal-title":"Asian Pac J Trop Med"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijantimicag.2017.08.009","article-title":"Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial.","volume":"51","author":"Majzoobi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.ijid.2011.12.003","article-title":"Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial.","volume":"16","author":"Hashemi","year":"2012","journal-title":"Int J Infect Dis"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/00365548.2014.918275","article-title":"Comparison of two durations of triple-drug therapy in patients with uncomplicated brucellosis: a randomized controlled trial.","volume":"46","author":"Sofian","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bjid.2016.02.004","article-title":"A randomized, comparative study of dual therapy (doxycycline-rifampin) versus triple therapy (doxycycline-rifampin-levofloxacin) for treating acute\/subacute brucellosis.","volume":"20","author":"Hasanain","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s15010-022-01806-x","article-title":"Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial.","volume":"50","author":"Majzoobi","year":"2022","journal-title":"Infection"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1742-1241.1973.tb09081.x","article-title":"A comparative study of therapeutic agents used for treatment of acute brucellosis.","volume":"27","author":"Feiz","year":"1973","journal-title":"Br J Clin Pract"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-4-18","article-title":"Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].","volume":"4","author":"Karabay","year":"2004","journal-title":"BMC Infect Dis"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-117-1-25","article-title":"Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. a randomized, double-blind study.","volume":"117","author":"Ariza","year":"1992","journal-title":"Ann Intern Med"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/infdis\/152.6.1358","article-title":"Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis.","volume":"152","author":"Ariza","year":"1985","journal-title":"J Infect Dis"},{"key":"R44-20250614","first-page":"360","article-title":"Comparative study of two regimens in the treatment of brucellosis.","volume":"6","author":"Rodriguez Zapata","year":"1987","journal-title":"Chemioterapia"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/23.3.433","article-title":"Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study.","volume":"23","author":"Acocella","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000238662","article-title":"Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis.","volume":"35","author":"Colmenero Castillo","year":"1989","journal-title":"Chemotherapy"},{"key":"R47-20250614","first-page":"649","article-title":"[A comparative therapeutic and multicenter trial of rifampicin and doxycycline versus streptomycin and doxycycline in human brucellosis].","volume":"96","author":"Solera","year":"1991","journal-title":"Med Clin (Barc)"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.37.9.1831","article-title":"Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.","volume":"37","author":"Akova","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/clind\/16.5.671","article-title":"Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis.","volume":"16","author":"Montejo","year":"1993","journal-title":"Clin Infect Dis"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/AAC.38.12.2798","article-title":"Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.","volume":"38","author":"Colmenero","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/AAC.39.9.2061","article-title":"Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.","volume":"39","author":"Solera","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0399-077X(96)80077-1","article-title":"Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis.","volume":"26","author":"Kalo","year":"1996","journal-title":"Med Mal Infect"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s100960050344","article-title":"Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis.","volume":"18","author":"Agalar","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R54-20250614","first-page":"921","article-title":"Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis.","volume":"23","author":"Saltoglu","year":"2002","journal-title":"Saudi Med J"},{"key":"R55-20250614","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/426024","article-title":"A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis.","volume":"39","author":"Solera","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R56-20250614","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1258\/004947505774938765","article-title":"Comparison of three different combination therapies in the treatment of human brucellosis.","volume":"35","author":"Ersoy","year":"2005","journal-title":"Trop Doct"},{"key":"R57-20250614","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.inf.0000219403.91975.ce","article-title":"Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis.","volume":"25","author":"Roushan","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R58-20250614","first-page":"889","article-title":"Comparison of two chemotherapy regimen: doxycycline-rifampicin and doxycycline cotrimoxazol in the brucellosis patients Ahvaz, Iran, 2004-2006.","volume":"23","author":"Ali Reza","year":"2007","journal-title":"Pak J Med Sci"},{"key":"R59-20250614","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1258\/td.2009.090030","article-title":"A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis.","volume":"39","author":"Keramat","year":"2009","journal-title":"Trop Doct"},{"key":"R60-20250614","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/jac\/dkq064","article-title":"Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial.","volume":"65","author":"Roushan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R61-20250614","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/2221-6189.288594","article-title":"Effect of 8-week and 12-week triple therapy (doxycycline, rifampicin, and gentamicin) on brucellosis: a comparative study.","volume":"9","author":"Karami","year":"2020","journal-title":"J Acute Dis"},{"key":"R62-20250614","first-page":"1","article-title":"Comparison Between Efficacy of Cipofoxacin Doxycycline and Rifampin - Doxycycline Regimens in Treatment and Relapse of Brucellosis. Abstracts of the 6th European Congress on Tropical Medicine and International Health and 1st Mediterranean Conference on Migration and Travel Health. Verona, Italy. September 6-10, 2009.","volume":"14","author":"Sarmadian","year":"2009","journal-title":"Trop Med Int Health"},{"key":"R65-20250614","first-page":"e01813","article-title":"Population pharmacokinetics of trimethoprim-sulfamethoxazole in infants and children.","volume":"62","author":"Autmizguine","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R66-20250614","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00002018-199920030-00005","article-title":"Antibacterial-induced nephrotoxicity in the newborn.","volume":"20","author":"Fanos","year":"1999","journal-title":"Drug Saf"},{"key":"R67-20250614","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40794-021-00130-w","article-title":"Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis.","volume":"7","author":"Alsubaie","year":"2021","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"R68-20250614","doi-asserted-by":"crossref","first-page":"e0012030","DOI":"10.1371\/journal.pntd.0012030","article-title":"Diagnosis of human brucellosis: systematic review and meta-analysis.","volume":"18","author":"Freire","year":"2024","journal-title":"PLoS NeglTrop Dis"},{"key":"R69-20250614","first-page":"e43758","article-title":"Comparison of the characteristics of Brucella patients diagnosed with blood culture positivity and\/or serology.","volume":"15","author":"Konya","year":"2023","journal-title":"Cureus"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:06:46Z","timestamp":1749942406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004389","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}